Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Authors:
- 25 September 2018
- journal article
- review article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 20 (7) , 514-518
Abstract
Importance: Benzodiazepines (BZs) are still widely prescribed for the treatment of anxiety disorders despite many publications in the literature which favour antidepressants (ADs) instead. What is the evidence? Observations: Treatment guidelines favour ADs over BZs for treatment of anxiety disorders without any head-to-head comparison of both drug groups with placebo. BZs are claimed to cause less efficacy and more safety issues than ADs, yet ADs also cause disturbing adverse events and, similar to BZs, discontinuation symptoms. Until evidence-based data become available, a look at two 6-month generalized anxiety disorder trials conducted by the same research group, one with a BZ and the other with an AD, might provide some guidance for the clinician. Most improvement with a BZ was obtained by 4 weeks, suggesting that BZ treatment longer than 4 weeks should only be offered to patients maximally improved at 4 weeks. In contrast, ADs may have to be prescribed for 3–6 months to obtain maximal benefits. Conclusion: Results of a controlled trial as proposed will go a long way in providing clinicians missing information to guide them in the appropriate use of both BZs and ADs in anxiety disorders.Keywords
This publication has 51 references indexed in Scilit:
- Benzodiazepines: Risks and benefits. A reconsiderationJournal of Psychopharmacology, 2013
- A Randomized, Naturalistic, Parallel-Group Study for the Long-Term Treatment of Panic Disorder With Clonazepam or ParoxetineJournal of Clinical Psychopharmacology, 2012
- What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re‐uptake inhibitorsAddiction, 2012
- Psychotropic Drug Prescribing in the United StatesJournal of Clinical Psychopharmacology, 2011
- Clinical Evaluation of the Daily Assessment of Symptoms‐Anxiety (DAS‐A): A New Instrument to Assess the Onset of Symptomatic Improvement in Generalized Anxiety DisorderCNS Neuroscience & Therapeutics, 2009
- Sertraline Treatment of Pathological GamblingThe Journal of Clinical Psychiatry, 2005
- Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia?American Journal of Psychiatry, 2003
- Drug Treatment of Panic Disorder: Comparative Efficacy of Alprazolam, Imipramine, and PlaceboThe British Journal of Psychiatry, 1992
- Withdrawal Reaction after Long-Term Therapeutic Use of BenzodiazepinesNew England Journal of Medicine, 1986
- Current Status of BenzodiazepinesNew England Journal of Medicine, 1983